Conditions: Type 2 Diabetes Mellitus
Keywords: diabetes exenatide Byetta sitagliptin Januvia Amylin Lilly
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 255
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether ceasing sitagliptin and switching to exenatide and metformin is non-inferior to adding exenatide to sitagliptin and metformin, in those patients with type 2 diabetes who are experiencing inadequate glycemic control with a combination of sitagliptin and metformin.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: exenatide and sitagliptin intervention 2: exenatide and placebo
Intervention descriptions: intervention 1: exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day intervention 2: exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day

Protocol document: